There were many interesting and thought-provoking discussions and speeches at the 19th EIHA Conference in Brussels this year. Various panel discussions covered topics ranging from seeds to finished products, including foods, textiles, and building materials. CBD Seed Europe was fortunate to be invited to speak on the breeding and genetics panel, where Francesco Folcarelli gave a speech and participated in the discussion.
During the panel, many subjects were addressed, such as the database for genotypes and phenotypes developed in the United States. This database outlines the different types of hemp and cannabis varieties and their distribution of THC, CBD, and other characteristics. The conversation then transitioned to the differences between hemp varieties for fiber and seeds versus hemp varieties for CBD extraction. Questions were raised about the price of seeds and whether they would decrease. Both camps agreed that the primary issue lies in the return on investment, with research and development costs being too high to allow for price reductions.
The discussion further delved into regulatory issues, specifically the blue label certification. Questions were directed to the European Commission regarding why certain strains are not yet listed on the common catalogue despite having the blue label certification. While answers have not yet been provided, CBD Seed Europe continues to engage with the Commission to ensure their strains are recognized and visible to customers. The team’s dedication to quality and compliance deserves acknowledgment by the European government.
